Natural Killer Cells for Cancer Immunotherapy

[1]  W. Pan,et al.  [Prognostic significance of natural killer cell infiltration in hepatocellular carcinoma]. , 2009, Ai zheng = Aizheng = Chinese journal of cancer.

[2]  M. Grever,et al.  A phase I trial of paclitaxel and trastuzumab in combination with interleukin-12 in patients with HER2/neu-expressing malignancies , 2009, Molecular Cancer Therapeutics.

[3]  W. Wels,et al.  Transfection with mRNA for CD19 specific chimeric antigen receptor restores NK cell mediated killing of CLL cells. , 2009, Leukemia research.

[4]  R. Negrin,et al.  Natural killer cells in allogeneic transplantation: effect on engraftment, graft- versus-tumor, and graft-versus-host responses. , 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[5]  M. Berg,et al.  Clinical-grade ex vivo-expanded human natural killer cells up-regulate activating receptors and death receptor ligands and have enhanced cytolytic activity against tumor cells. , 2009, Cytotherapy.

[6]  T. Waldmann,et al.  Interleukin-15 combined with an anti-CD40 antibody provides enhanced therapeutic efficacy for murine models of colon cancer , 2009, Proceedings of the National Academy of Sciences.

[7]  E. Andrès,et al.  CD56bright natural killer (NK) cells: an important NK cell subset , 2009, Immunology.

[8]  J. Lennerz,et al.  A human natural killer cell subset provides an innate source of IL-22 for mucosal immunity , 2009, Nature.

[9]  Peter Parham,et al.  Donors with group B KIR haplotypes improve relapse-free survival after unrelated hematopoietic cell transplantation for acute myelogenous leukemia. , 2009, Blood.

[10]  Joseph C. Sun,et al.  Adaptive Immune Features of Natural Killer Cells , 2009, Nature.

[11]  T. Robak,et al.  Toll-like receptors and their role in carcinogenesis and anti-tumor treatment , 2008, Cellular & Molecular Biology Letters.

[12]  L. Moretta,et al.  Histone deacetylase inhibitors sensitize tumour cells for cytotoxic effects of natural killer cells. , 2008, Cancer letters.

[13]  M. Caligiuri,et al.  Human natural killer cells. , 2008, Blood.

[14]  A. Ashkenazi,et al.  Ligand-based targeting of apoptosis in cancer: the potential of recombinant human apoptosis ligand 2/Tumor necrosis factor-related apoptosis-inducing ligand (rhApo2L/TRAIL). , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  George Muller,et al.  Lenalidomide Enhances Natural Killer Cell and Monocyte-Mediated Antibody-Dependent Cellular Cytotoxicity of Rituximab-Treated CD20+ Tumor Cells , 2008, Clinical Cancer Research.

[16]  M. Mason,et al.  Human Tumor-Derived Exosomes Down-Modulate NKG2D Expression1 , 2008, The Journal of Immunology.

[17]  J. Hanna,et al.  Correction: Harnessing Soluble NK Cell Killer Receptors for the Generation of Novel Cancer Immune Therapy , 2008, PloS one.

[18]  N. Greenberg,et al.  NKG2D-deficient mice are defective in tumor surveillance in models of spontaneous malignancy. , 2008, Immunity.

[19]  M. Smyth,et al.  Interleukin 21: combination strategies for cancer therapy , 2008, Nature Reviews Drug Discovery.

[20]  W. Wels,et al.  Expression of a CD20-specific chimeric antigen receptor enhances cytotoxic activity of NK cells and overcomes NK-resistance of lymphoma and leukemia cells , 2008, Cancer Immunology, Immunotherapy.

[21]  G. Altavilla,et al.  Natural killer cells infiltrating human nonsmall‐cell lung cancer are enriched in CD56brightCD16− cells and display an impaired capability to kill tumor cells , 2008, Cancer.

[22]  L. Moretta,et al.  Mesenchymal stem cells inhibit natural killer-cell proliferation, cytotoxicity, and cytokine production: role of indoleamine 2,3-dioxygenase and prostaglandin E2. , 2008, Blood.

[23]  B. Barlogie,et al.  Bortezomib down-regulates the cell-surface expression of HLA class I and enhances natural killer cell-mediated lysis of myeloma. , 2008, Blood.

[24]  S. Cullen,et al.  Mechanisms of granule-dependent killing , 2008, Cell Death and Differentiation.

[25]  Michael Hallek,et al.  Human leukocyte antigen-B-associated transcript 3 is released from tumor cells and engages the NKp30 receptor on natural killer cells. , 2007, Immunity.

[26]  D. Lawrence,et al.  Cooperation of the proapoptotic receptor agonist rhApo2L/TRAIL with the CD20 antibody rituximab against non-Hodgkin lymphoma xenografts. , 2007, Blood.

[27]  M. Czuczman,et al.  Immunomodulatory drugs stimulate natural killer‐cell function, alter cytokine production by dendritic cells, and inhibit angiogenesis enhancing the anti‐tumour activity of rituximab in vivo , 2007, British journal of haematology.

[28]  Jonathan P Butchar,et al.  The Activation of Natural Killer Cell Effector Functions by Cetuximab-Coated, Epidermal Growth Factor Receptor–Positive Tumor Cells is Enhanced By Cytokines , 2007, Clinical Cancer Research.

[29]  Tadanori Mayumi,et al.  Immune Cell Recruitment and Cell-Based System for Cancer Therapy , 2007, Pharmaceutical Research.

[30]  G. Morgan,et al.  The requirement for DNAM-1, NKG2D, and NKp46 in the natural killer cell-mediated killing of myeloma cells. , 2007, Cancer research.

[31]  A. Santoni,et al.  Natural Killer (NK) Cells from Killers to Regulators: Distinct Features Between Peripheral Blood and Decidual NK Cells , 2007, American journal of reproductive immunology.

[32]  T. Enver,et al.  CD56bright Human NK Cells Differentiate into CD56dim Cells: Role of Contact with Peripheral Fibroblasts , 2007, The Journal of Immunology.

[33]  J. Trowsdale,et al.  Reciprocal regulation of human natural killer cells and macrophages associated with distinct immune synapses. , 2007, Blood.

[34]  Eric O Long.  Ready for prime time: NK cell priming by dendritic cells. , 2007, Immunity.

[35]  A. Diefenbach,et al.  Dendritic cells prime natural killer cells by trans-presenting interleukin 15. , 2007, Immunity.

[36]  I. Flinn,et al.  Systemic Interleukin-2 and Adoptive Transfer of Lymphokine-Activated Killer Cells Improves Antibody-Dependent Cellular Cytotoxicity in Patients with Relapsed B-Cell Lymphoma Treated with Rituximab , 2007, Clinical Cancer Research.

[37]  J. Wagner,et al.  Good manufacturing practices production of natural killer cells for immunotherapy: a six‐year single‐institution experience , 2007, Transfusion.

[38]  Stephen B Fox,et al.  Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  L. Zitvogel,et al.  The role of regulatory T cells in the control of natural killer cells: relevance during tumor progression , 2006, Immunological reviews.

[40]  M. Caligiuri,et al.  A Phase 2 Study of Rituximab in Combination with Recombinant Interleukin-2 for Rituximab-Refractory Indolent Non-Hodgkin's Lymphoma , 2006, Clinical Cancer Research.

[41]  Eric O Long,et al.  Activation, coactivation, and costimulation of resting human natural killer cells , 2006, Immunological reviews.

[42]  T. Whiteside,et al.  In vivo migration of labeled autologous natural killer cells to liver metastases in patients with colon carcinoma , 2006, Journal of Translational Medicine.

[43]  S. Ansell,et al.  Randomized Phase II Study of Interleukin-12 in Combination with Rituximab in Previously Treated Non-Hodgkin's Lymphoma Patients , 2006, Clinical Cancer Research.

[44]  A. Cumano,et al.  A thymic pathway of mouse natural killer cell development characterized by expression of GATA-3 and CD127 , 2006, Nature Immunology.

[45]  O. Mandelboim,et al.  Tumor and viral recognition by natural killer cells receptors. , 2006, Seminars in cancer biology.

[46]  A. Bossler,et al.  Oligodeoxynucleotide CpG 7909 Delivered as Intravenous Infusion Demonstrates Immunologic Modulation in Patients With Previously Treated Non-Hodgkin Lymphoma , 2006, Journal of immunotherapy.

[47]  A. Keating,et al.  Constitutively polarized granules prime KHYG-1 NK cells. , 2006, International immunology.

[48]  H. Fujii,et al.  CD4(+)CD25high regulatory T cells increase with tumor stage in patients with gastric and esophageal cancers , 2006, Cancer Immunology, Immunotherapy.

[49]  F. Re,et al.  Killer cell Ig‐like receptors ligand‐mismatched, alloreactive natural killer cells lyse primary solid tumors , 2006, Cancer.

[50]  D. Schrump,et al.  Bortezomib and depsipeptide sensitize tumors to tumor necrosis factor-related apoptosis-inducing ligand: a novel method to potentiate natural killer cell tumor cytotoxicity. , 2006, Cancer research.

[51]  W. Carson,et al.  Interleukin-21 Enhances NK Cell Activation in Response to Antibody-Coated Targets1 , 2006, The Journal of Immunology.

[52]  F. Hodi,et al.  Therapy-induced antibodies to MHC class I chain-related protein A antagonize immune suppression and stimulate antitumor cytotoxicity. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[53]  C. Sheridan.  First-in-class cancer therapeutic to stimulate natural killer cells. , 2006, Nature biotechnology.

[54]  Roberta Castriconi,et al.  Surface NK receptors and their ligands on tumor cells. , 2006, Seminars in immunology.

[55]  S. Rosenberg,et al.  IL-2 administration increases CD4+ CD25(hi) Foxp3+ regulatory T cells in cancer patients. , 2006, Blood.

[56]  M. Smyth,et al.  CD27 Dissects Mature NK Cells into Two Subsets with Distinct Responsiveness and Migratory Capacity1 , 2006, The Journal of Immunology.

[57]  P. Nelson,et al.  Cytotoxic Markers and Frequency Predict Functional Capacity of Natural Killer Cells Infiltrating Renal Cell Carcinoma , 2006, Clinical Cancer Research.

[58]  G. Zografos,et al.  Cytolytic and Cytotoxic Activity of a Human Natural Killer Cell Line Genetically Modified to Specifically Recognize HER-2/neu Overexpressing Tumor Cells , 2006, Immunopharmacology and immunotoxicology.

[59]  A. Keating,et al.  Irradiated KHYG-1 retains cytotoxicity: Potential for adoptive immunotherapy with a natural killer cell line , 2006, International journal of radiation biology.

[60]  J. Berzofsky,et al.  Lymphopenia and interleukin-2 therapy alter homeostasis of CD4+CD25+ regulatory T cells , 2005, Nature Medicine.

[61]  M. Smyth,et al.  NKG2D function protects the host from tumor initiation , 2005, The Journal of experimental medicine.

[62]  W. Carson,et al.  CpG-Containing Oligodeoxynucleotides Act through TLR9 to Enhance the NK Cell Cytokine Response to Antibody-Coated Tumor Cells 1 , 2005, The Journal of Immunology.

[63]  Michael Bitzer,et al.  Natural killer cell-mediated lysis of hepatoma cells via specific induction of NKG2D ligands by the histone deacetylase inhibitor sodium valproate. , 2005, Cancer research.

[64]  P. Debré,et al.  NK-cell reconstitution after haploidentical hematopoietic stem-cell transplantations: immaturity of NK cells and inhibitory effect of NKG2A override GvL effect. , 2005, Blood.

[65]  Jung‐Ta Chen,et al.  Prognostic significance of intratumoral natural killer cells in primary resected esophageal squamous cell carcinoma. , 2005, Chang Gung medical journal.

[66]  M. Smyth,et al.  KHYG-1, a model for the study of enhanced natural killer cell cytotoxicity. , 2005, Experimental hematology.

[67]  C. Le,et al.  Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. , 2005, Blood.

[68]  Peter Parham,et al.  Complex interactions: the immunogenetics of human leukocyte antigen and killer cell immunoglobulin-like receptors. , 2005, Seminars in hematology.

[69]  P. Parham.  MHC class I molecules and kirs in human history, health and survival , 2005, Nature Reviews Immunology.

[70]  E. Lanino,et al.  Analysis of the receptor-ligand interactions in the natural killer-mediated lysis of freshly isolated myeloid or lymphoblastic leukemias: evidence for the involvement of the Poliovirus receptor (CD155) and Nectin-2 (CD112). , 2005, Blood.

[71]  T. Waldmann,et al.  Role of trans-cellular IL-15 presentation in the activation of NK cell-mediated killing, which leads to enhanced tumor immunosurveillance. , 2005, Blood.

[72]  George Coukos,et al.  Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival , 2004, Nature Medicine.

[73]  C. Shapiro,et al.  A Phase I Study of Interleukin 12 with Trastuzumab in Patients with Human Epidermal Growth Factor Receptor-2-Overexpressing Malignancies , 2004, Clinical Cancer Research.

[74]  J. Blay,et al.  Novel mode of action of c-kit tyrosine kinase inhibitors leading to NK cell-dependent antitumor effects. , 2004, The Journal of clinical investigation.

[75]  A. Difrancesco,et al.  Phase I Studies of Interleukin (IL)-2 and Rituximab in B-Cell Non-Hodgkin’s Lymphoma , 2004, Clinical Cancer Research.

[76]  M. Smyth,et al.  Innate Immune Surveillance of Spontaneous B Cell Lymphomas by Natural Killer Cells and γδ T Cells , 2004, The Journal of experimental medicine.

[77]  M. Doubrovin,et al.  Evasion from NK Cell Immunity by MHC Class I Chain-Related Molecules Expressing Colon Adenocarcinoma 1 , 2003, The Journal of Immunology.

[78]  P. Kuppen,et al.  NK cells and the tumour microenvironment: implications for NK-cell function and anti-tumour activity. , 2003, Trends in immunology.

[79]  Steven A. Rosenberg,et al.  Adoptive-cell-transfer therapy for the treatment of patients with cancer , 2003, Nature Reviews Cancer.

[80]  M. Caligiuri,et al.  CD56bright natural killer cells are present in human lymph nodes and are activated by T cell-derived IL-2: a potential new link between adaptive and innate immunity. , 2003, Blood.

[81]  H. Kirchner,et al.  Large-scale generation of natural killer lymphocytes for clinical application. , 2002, Journal of hematotherapy & stem cell research.

[82]  J. Gribben,et al.  Combination immunotherapy with rituximab and interleukin 2 in patients with relapsed or refractory follicular non‐Hodgkin's lymphoma , 2002, British journal of haematology.

[83]  Katia Perruccio,et al.  Effectiveness of Donor Natural Killer Cell Alloreactivity in Mismatched Hematopoietic Transplants , 2002, Science.

[84]  G. Salles,et al.  Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. , 2002, Blood.

[85]  M. Robertson.  Role of chemokines in the biology of natural killer cells , 2002, Journal of leukocyte biology.

[86]  E. Seifried,et al.  Cellular immunotherapy of malignancies using the clonal natural killer cell line NK-92. , 2001, Journal of hematotherapy & stem cell research.

[87]  M. Pfreundschuh,et al.  Anti-CD16/CD30 bispecific antibody treatment for Hodgkin's disease: role of infusion schedule and costimulation with cytokines. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[88]  W. Murphy,et al.  Augmentation of antitumor effects by NK cell inhibitory receptor blockade in vitro and in vivo. , 2001, Blood.

[89]  K. Nakachi,et al.  Natural cytotoxic activity of peripheral-blood lymphocytes and cancer incidence: an 11-year follow-up study of a general population , 2000, The Lancet.

[90]  L. Presta,et al.  Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets , 2000, Nature Medicine.

[91]  S. Natsugoe,et al.  Prognostic value of intratumoral natural killer cells in gastric carcinoma , 2000, Cancer.

[92]  V. Ho,et al.  Immunotherapy of malignant melanoma in a SCID mouse model using the highly cytotoxic natural killer cell line NK-92. , 1999, Journal of hematotherapy.

[93]  P. Steinherz,et al.  Antileukemia activity of a natural killer cell line against human leukemias. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[94]  S. Pestka,et al.  Tumor cell responses to IFNgamma affect tumorigenicity and response to IL-12 therapy and antiangiogenesis. , 1998, Immunity.

[95]  P. Robbins,et al.  Stable transduction of the interleukin-2 gene into human natural killer cell lines and their phenotypic and functional characterization in vitro and in vivo. , 1998, Blood.

[96]  J. Bell,et al.  HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C , 1998, Nature.

[97]  M. A. Sáez,et al.  The prognostic significance of intratumoral natural killer cells in patients with colorectal carcinoma , 1997, Cancer.

[98]  C. Verfaillie,et al.  Low dose subcutaneous interleukin-2 after autologous transplantation generates sustained in vivo natural killer cell activity. , 1997, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[99]  T. George,et al.  Role of murine NK cells and their receptors in hybrid resistance. , 1997, Current opinion in immunology.

[100]  H. Klingemann,et al.  A cytotoxic NK-cell line (NK-92) for ex vivo purging of leukemia from blood. , 1996, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[101]  Caligiuri,et al.  Natural Killer Cell Subsets and Development , 1996, Methods.

[102]  E. Borden,et al.  Inhibition of angiogenesis by interferons: effects on tumor- and lymphocyte-induced vascular responses. , 1987, Cancer research.

[103]  H. Ljunggren,et al.  Selective rejection of H–2-deficient lymphoma variants suggests alternative immune defence strategy , 1986, Nature.

[104]  R. Herberman,et al.  Natural cytotoxic reactivity of mouse lymphoid cells against syngeneic and allogeneic tumors. I. Distribution of reactivity and specificity , 1975, International journal of cancer.

[105]  R. Kiessling,et al.  „Natural”︁ killer cells in the mouse. I. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Specificity and distribution according to genotype , 1975, European journal of immunology.

[106]  H. Klingemann,et al.  Infusion of the allogeneic cell line NK-92 in patients with advanced renal cell cancer or melanoma: a phase I trial. , 2008, Cytotherapy.

[107]  Daniel Olive,et al.  Deficient expression of NCR in NK cells from acute myeloid leukemia: Evolution during leukemia treatment and impact of leukemia cells in NCRdull phenotype induction. , 2007, Blood.

[108]  T. Wu,et al.  Immunotherapeutic strategies employing RNA interference technology for the control of cancers. , 2007, Journal of biomedical science.

[109]  Christopher B Wilson,et al.  Regulation of interferon-gamma during innate and adaptive immune responses. , 2007, Advances in immunology.

[110]  G. Nuovo,et al.  Natural killer cells produce T cell-recruiting chemokines in response to antibody-coated tumor cells. , 2006, Cancer research.

[111]  Eric O Long,et al.  Synergy among receptors on resting NK cells for the activation of natural cytotoxicity and cytokine secretion. , 2006, Blood.

[112]  Lewis L Lanier,et al.  NK cell recognition. , 2005, Annual review of immunology.

[113]  Jeffrey S. Miller,et al.  FLT3 ligand administration after hematopoietic cell transplantation increases circulating dendritic cell precursors that can be activated by CpG oligodeoxynucleotides to enhance T-cell and natural killer cell function. , 2005, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[114]  R. Sun,et al.  Characterization of interleukin-15 gene-modified human natural killer cells: implications for adoptive cellular immunotherapy. , 2004, Haematologica.

[115]  H. Klingemann,et al.  Ex vivo expansion of the highly cytotoxic human natural killer-92 cell-line under current good manufacturing practice conditions for clinical adoptive cellular immunotherapy. , 2003, Cytotherapy.

[116]  S. Coca,et al.  Prognostic significance of tumor infiltrating natural killer cells subset CD57 in patients with squamous cell lung cancer. , 2002, Lung cancer.